Here are the top 5 biosimilar articles for the week of April 26, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of April 26, 2021.
Number 5: New Brunswick, Canada, has become the third Canadian province to implement a “switching” policy that mandates the use of money-saving biosimilars for patients with inflammatory diseases.
Number 4: The European Union is a diverse market with pockets of biosimilar resistance but also cost-saving triumphs, panelists said at the Biosimilar Medicines Virtual Summit 2021.
Number 3: The savings from pegfilgrastim biosimilars rapidly add up, according to a study simulation that accounted for hospital costs associated with the on-body injector.
Number 2: Samsung Bioepis has garnered International Forum (iF) Design Award 2021 honors for its biosimilars packaging, which features soft shapes and soothing mono-colors.
Number 1: An ongoing real-world observational study of bevacizumab biosimilar (Mvasi) vs originator (Avastin) has demonstrated comparable safety and effectiveness for a cohort of patients with metastatic colorectal cancer.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.